TP53 and head and neck squamous cell carcinoma: Several studies using pre-clinical models also demonstrated that HNSCC with wild type PI3KCA is sensitive to PI3K/mTOR inhibitors, particularly in combination with a MEK inhibitor or in combination with radiation in the context of wild type p53 [58, 59].